Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

FOSTER CITY, Calif.,& RAHWAY, N.J.--(BUSINESS WIRE) March 06, 2024 -- Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2 clinical study...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials